Janssen Korea has received domestic approval for a new prostate cancer drug. The emergence of new options after Zytiga (Abiraterone acetate) is expected to expand its influence in the prostate cancer treatment market.

The MFDS approved Janssen's Erleada (Apalutamide) in Korea on the 30th. It is approved as a combination therapy with androgen blockade (ADT) in the treatment of patients with hormone-responsive metastatic prostate cancer (mHSPC).

The recommended dose is Erleada 240mg once a day (4 tablets of 60mg).

Erleada proved its effectiveness through a phase III SPARTAN study. In the SPARTAN study, the Erleada-treated group had a 72% reduction in the incidence of distant